



شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم



شبكة المعلومات الجامعية  
@ ASUNET



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



شبكة المعلومات الجامعية

# جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأفلام قد أعدت دون أية تغييرات



## يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of  
15-25- c and relative humidity 20-40%

# بعض الوثائق الأصلية تالفة

# بالرسالة صفحات لم ترد بالاصل

# **"ANALYTICAL STUDY ON SOME ANTI- INFLAMMATORY DRUGS"**

*Thesis presented by*

615, 19

Nour EL-Deen Wageih Sayed

B.Pharm.Sci. Cairo University

(1996)

M.Sc. Pharm. Sci. Cairo University

(2001)

For Fulfillment of the  
degree of Philosophy doctor In Pharmaceutical Sciences

"Analytical Chemistry "

Under the supervision of

**Prof.Dr. Badr E.Elzeany**

Professor of Analytical Chemistry

Faculty of Pharmacy

Cairo University

**Prof.Dr. Mohamed A.Elkawy**

Professor of Analytical Chemistry

Faculty of Pharmacy

Cairo University

**Dr. Nagiba Y. Hasan**

Lecturer of Analytical Chemistry

Faculty of Pharmacy


Cairo University

# APPROVAL SHEET

This thesis has been approved on     /     / 2005 by the committee in charge.


**Prof.Dr. Badr E.El-Zeany**

Head of Analytical Chemistry Department  
Faculty of Pharmacy  
Cairo University




**Prof.Dr. Mohamed A.El-kawy**

Professor of Analytical Chemistry  
Faculty of Pharmacy  
Cairo University




**Prof.Dr. Abdelkader Sayed Ahmad**

Professor of Analytical Chemistry  
Faculty of Pharmacy  
Cairo University



**Prof.Dr. Hamed Mahmoud El-fatatry**

Professor of Analytical Chemistry  
Faculty of Pharmacy  
Tanta University



# ***LIST OF CONTENTS***

|                |          |
|----------------|----------|
| <b>PREFACE</b> | <b>1</b> |
|----------------|----------|

## **PART I: GENERAL INTRODUCTION**

|                                                                 |          |
|-----------------------------------------------------------------|----------|
| <b>I.1. Anti-inflammatory drugs</b>                             | <b>3</b> |
| I.1.1. Historical                                               | 3        |
| I.1.2. Definition and classification of anti-inflammatory drugs | 5        |
| <b>I.2. Stability indicating methods</b>                        | <b>7</b> |
| I.2.1. Concepts in drug stability                               | 7        |
| I.2.2. Stability indicating methods of analysis                 | 7        |

## **PART II: STABILITY INDICATING METHODS FOR THE DETERMINATION OF ACECLOFENAC**

|                                           |           |
|-------------------------------------------|-----------|
| <b>II.1.0 LITERATURE REVIEW</b>           | <b>13</b> |
| II.1.1 STRUCTURE                          | 13        |
| II.1.2 PROPERTIES                         | 13        |
| II.1.3 PHARMACOLOGY                       | 13        |
| II.1.4 METHODS OF ANALYSIS                | 14        |
| <b>II.2.0 EXPERIMENTAL STUDY</b>          | <b>16</b> |
| II.2.1.0. Samples, reagents and apparatus | 16        |
| II.2.2.0. Procedures                      | 17        |
| <b>II.3.0. RESULTS AND DISCUSSION</b>     | <b>22</b> |
| II.3.1. Degradation of aceclofenac        | 22        |
| II.3.2. Chemometric methods               | 22        |
| II.3.3. Bivariate calibration method      | 33        |
| II.3.4. Statistical analysis              | 37        |

## **PART III: STABILITY INDICATING METHODS FOR THE DETERMINATION OF LORNOXICAM**

|                                   |           |
|-----------------------------------|-----------|
| <b>III.1.0 LITERATURE REVIEW</b>  | <b>42</b> |
| III.1.1 STRUCTURE                 | 42        |
| III.1.2 PROPERTIES                | 42        |
| III.1.3 PHARMACOLOGY              | 42        |
| III.1.4 METHODS OF ANALYSIS       | 42        |
| <b>III.2.0 EXPERIMENTAL STUDY</b> | <b>44</b> |

|                                               |    |
|-----------------------------------------------|----|
| III.2.1.0. Samples, reagents and apparatus    | 44 |
| III.2.2.0. Procedures                         | 47 |
| III.3.0. RESULTS AND DISCUSSION               | 53 |
| III.3.1. Degradation of lornoxicam            | 53 |
| III.3.2. Zero order spectrophotometric method | 57 |
| III.3.3. Densitometric method                 | 64 |
| III.3.4. HPLC method                          | 71 |
| III.3.5. Statistical analysis                 | 78 |

## **PART IV: STABILITY INDICATING METHODS FOR THE DETERMINATION OF PIROXICAM**

|                                                                                 |     |
|---------------------------------------------------------------------------------|-----|
| IV.1.0 LITERATURE REVIEW                                                        | 80  |
| IV.1.1 STRUCTURE                                                                | 80  |
| IV.1.2 PROPERTIES                                                               | 80  |
| IV.1.3 PHARMACOLOGY                                                             | 80  |
| IV.1.4 METHODS OF ANALYSIS                                                      | 81  |
| IV.2.0 EXPERIMENTAL STUDY                                                       | 88  |
| IV.2.1.0. Samples, reagents and apparatus                                       | 88  |
| IV.2.2.0. Procedures                                                            | 92  |
| IV.3.0. RESULTS AND DISCUSSION                                                  | 100 |
| IV.3.1. Degradation of piroxicam                                                | 100 |
| IV.3.2. First( $D_1$ ) derivative spectrophotometric method                     | 104 |
| IV.3.3. Ratio-spectra first derivative ( $RSD_1$ )<br>spectrophotometric method | 108 |
| IV.3.4. chemometric methods                                                     | 115 |
| IV.3.5. Densitometric method                                                    | 130 |
| IV.3.6. HPLC method                                                             | 130 |
| IV.3.7. Statistical analysis                                                    | 144 |

|          |     |
|----------|-----|
| APPENDIX | 146 |
|----------|-----|

|            |     |
|------------|-----|
| REFERENCES | 152 |
|------------|-----|

## ***LIST OF FIGURES***

- Figure (1): Zero-order spectra of the ethanolic solutions of intact aceclofenac ( $30 \mu\text{g. ml}^{-1}$ ) and its degradate ( $5 \mu\text{g. ml}^{-1}$ ). 23
- Figure (2): RMSEC plot of the cross validation results of the training set as a function of the number of principle components used to construct the PCR calibration for aceclofenac. 26
- Figure (3): RMSEC plot of the cross validation results of the training set as a function of the number of principle components used to construct the PLS calibration for aceclofenac. 26
- Figure (4): Predicted concentration versus actual concentration of aceclofenac in the validation set using CLS method. 29
- Figure (5): Predicted concentration versus actual concentration of aceclofenac in the validation set using PCR method. 29
- Figure (6): Predicted concentration versus actual concentration of aceclofenac in the validation set using PLS method. 30
- Figure (7): concentration residuals versus actual concentration of aceclofenac in the validation set using CLS method. 30
- Figure (8): concentration residuals versus actual concentration of aceclofenac in the validation set using PCR method. 31
- Figure (9): concentration residuals versus actual concentration of aceclofenac in the validation set using PLS method. 31
- Figure (10): The proposed pathway of lornoxicam degradation. 54
- Figure (11): Thin layer chromatogram of lornoxicam and its degradates using chloroform: methanol (95:5 v/v) as mobile phase. 55
- Figure (12): IR spectra of lornoxicam and its degradates. 56

|                                                                                                                                                                                                                                                       |     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Figure (13): Zero-order spectra of Intact lornoxicam ( $5 \mu\text{g. ml}^{-1}$ ) and its degradates ( $5 \mu\text{g. ml}^{-1}$ ).                                                                                                                    | 58  |
| Figure (14): Linearity of the peak amplitudes at 380 nm to the concentration of intact lornoxicam.                                                                                                                                                    | 59  |
| Figure (15): Scanning profile of a TLC chromatogram of lornoxicam.                                                                                                                                                                                    | 65  |
| Figure (16): Linearity of the peak area to the concentration of pure lornoxicam.                                                                                                                                                                      | 66  |
| Figure (17): HPLC chromatograms of lornoxicam( $5\mu\text{g. ml}^{-1}$ ) and its degradates ( $5\mu\text{g. ml}^{-1}$ ).                                                                                                                              | 72  |
| Figure (18): Linearity of the peak area to the concentration of pure lornoxicam.                                                                                                                                                                      | 73  |
| Figure (19): The proposed pathway of piroxicam degradation.                                                                                                                                                                                           | 101 |
| Figure (20): Thin layer chromatogram of piroxicam and its degradation products using chloroform: methanol (95:5 v/v) as mobile phase.                                                                                                                 | 102 |
| Figure (21): IR spectra of piroxicam and its degradates.                                                                                                                                                                                              | 103 |
| Figure (22): Zero-order spectra of the ethanolic solutions of piroxicam ( $12 \mu\text{g. ml}^{-1}$ ) and its degradates ( $5 \mu\text{g. ml}^{-1}$ ).                                                                                                | 105 |
| Figure (23): First derivative spectra of the ethanolic solutions of Intact piroxicam ( $12 \mu\text{g. ml}^{-1}$ ) and its degradates ( $5\mu\text{g. ml}^{-1}$ ).                                                                                    | 106 |
| Figure (24): Linearity of the peak amplitudes at 345 nm to the concentration of intact piroxicam.                                                                                                                                                     | 107 |
| Figure (25): Ratio-spectra & first derivative curves of the ethanolic solutions of Intact piroxicam ( $12 \mu\text{g. ml}^{-1}$ ) and its degradates ( $10\mu\text{g.ml}^{-1}$ ) using $10\mu\text{g.ml}^{-1}$ of the first degradate as the divisor. | 113 |
| Figure (26): Linearity of the peak amplitudes at 358 nm to the concentration of intact piroxicam.                                                                                                                                                     | 114 |

|                                                                                                                                                                                      |     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Figure (27): RMSEC plot of the cross validation results of the training set as a function of the number of principle components used to construct the PCR calibration for piroxicam. | 122 |
| Figure (28): RMSEC plot of the cross validation results of the training set as a function of the number of principle components used to construct the PLS calibration for piroxicam. | 122 |
| Figure (29): Predicted concentration versus actual concentration of piroxicam in the validation set using CLS method.                                                                | 124 |
| Figure (30): Predicted concentration versus actual concentration of piroxicam in the validation set using PCR method.                                                                | 124 |
| Figure (31): Predicted concentration versus actual concentration of piroxicam in the validation set using PLS method.                                                                | 125 |
| Figure (32): concentration residuals versus actual concentration of piroxicam in the validation set using CLS method.                                                                | 125 |
| Figure (33): concentration residuals versus actual concentration of piroxicam in the validation set using PCR method.                                                                | 126 |
| Figure (34): concentration residuals versus actual concentration of piroxicam in the validation set using PLS method.                                                                | 126 |
| Figure (35): Scanning profile of a TLC chromatogram of piroxicam.                                                                                                                    | 131 |
| Figure (36): Linearity of the peak area to the concentration of pure piroxicam.                                                                                                      | 132 |
| Figure (37): HPLC chromatograms of piroxicam( $5\mu\text{g. ml}^{-1}$ ) and its degradates ( $5\mu\text{g. ml}^{-1}$ ).                                                              | 138 |
| Figure (38): Linearity of the peak area to the concentration of pure piroxicam.                                                                                                      | 139 |

## ***LIST OF TABLES***

|                                                                                                                                                                                                                             |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Table (1): The concentration of different mixtures of aceclofenac and its degradate used in the training set.                                                                                                               | 24 |
| Table (2): Results of the analysis of the mixtures of the validation set of aceclofenac by the proposed method.                                                                                                             | 27 |
| Table (3): RMSEP and $Q^2$ values of the validation set analysis of aceclofenac by the proposed methods.                                                                                                                    | 32 |
| Table (4): Determination of aceclofenac in Bristafam tablets by the proposed chemometric methods compared with the official B.P. (1998) method.                                                                             | 34 |
| Table (5): Application of standard addition technique to the analysis of aceclofenac by the proposed chemometric methods.                                                                                                   | 35 |
| Table (6): Application of the method of Kaiser for the selection of the wavelength set for the mixture aceclofenac (AC)-degradate (DC): the absolute values of determinants of sensitivity matrices ( $K \times 10^{-6}$ ). | 36 |
| Table (7): Linear regression calibration formulae used for the bivariate algorithm.                                                                                                                                         | 38 |
| Table (8): Determination of aceclofenac in laboratory prepared mixtures by the proposed bivariate method.                                                                                                                   | 38 |
| Table (9): Determination of aceclofenac in Bristafam tablets by the proposed bivariate spectrophotometric method compared with the official B.P. (1998) method.                                                             | 39 |
| Table (10): Application of the standard addition technique to the analysis of aceclofenac by the proposed bivariate spectrophotometric method.                                                                              | 40 |
| Table (11): Statistical analysis of the results obtained by the proposed methods and B.P.(1998) method for the determination of aceclofenac.                                                                                | 41 |

|                                                                                                                                                  |    |
|--------------------------------------------------------------------------------------------------------------------------------------------------|----|
| Table (12): Accuracy of the proposed zero order spectrophotometric method for the analysis of pure samples of lornoxicam.                        | 60 |
| Table(13): Determination of lornoxicam in laboratory prepared mixtures with its degradates by the proposed zero order spectrophotometric method. | 61 |
| Table (14): Determination of lornoxicam in pharmaceutical formulations by the proposed zero order spectrophotometric method.                     | 62 |
| Table (15): Application of the standard addition technique to the analysis of lornoxicam by zero order spectrophotometric method.                | 63 |
| Table (16): Accuracy of the proposed densitometric method for the analysis of pure samples of lornoxicam.                                        | 67 |
| Table(17): Determination of lornoxicam in laboratory prepared mixtures with its degradate by the proposed densitometric method.                  | 68 |
| Table (18): Determination of lornoxicam in pharmaceutical formulations by the proposed densitometric method compared with the reference method.  | 69 |
| Table (19): Application of standard addition technique to the analysis of lornoxicam by densitometric method.                                    | 70 |
| Table (20): Accuracy of the proposed HPLC method for the analysis of pure samples of lornoxicam.                                                 | 74 |
| Table (21): Determination of lornoxicam in laboratory prepared mixtures with its degradate by the proposed HPLC method.                          | 75 |
| Table (22):Determination of lornoxicam in pharmaceutical formulations by the proposed HPLC method compared with the reference method.            | 76 |

|                                                                                                                                                                      |     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Table (23): Application of standard addition technique to the analysis of lornoxicam by HPLC method.                                                                 | 77  |
| Table (24): Statistical analysis of the results obtained by the proposed methods and the reference method for the determination of lornoxicam.                       | 79  |
| Table (25): Accuracy of the proposed $D_1$ spectrophotometric method for the analysis of pure samples of piroxicam.                                                  | 109 |
| Table (26): Determination of piroxicam in laboratory prepared mixtures with its degradates by the proposed first derivative spectrophotometric method.               | 110 |
| Table (27): Determination of piroxicam in pharmaceutical formulations by the proposed first derivative spectrophotometric method compared with the reference method. | 111 |
| Table (28): Application of the standard addition technique to the analysis of piroxicam by first derivative spectrophotometric method.                               | 112 |
| Table (29): Accuracy of the proposed $RSD_1$ spectrophotometric method for the analysis of pure samples of piroxicam.                                                | 116 |
| Table (30): Determination of piroxicam in laboratory prepared mixtures with its degradates by the proposed $RSD_1$ spectrophotometric method.                        | 117 |
| Table (31): Determination of piroxicam in pharmaceutical formulations by the proposed $RSD_1$ spectrophotometric method compared with the reference method.          | 118 |
| Table (32): Application of standard addition technique to the analysis of piroxicam by $RSD_1$ spectrophotometric method.                                            | 119 |
| Table (33): The concentration of different mixtures of piroxicam and its degradates used in the training set.                                                        | 120 |